ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) announced Tuesday that its wholly-owned subsidiary Talem Therapeutics signed a new agreement with Ligand Pharmaceuticals (NASDAQ:LGND) for its novel OmniAb platform.
Ligand’s OmniAb is a genetically engineered platform for the generation of diverse human antibodies. It is the only platform comprised of three species of rats, mice and chickens.
Under the agreement, Talem will access OmniAb to use with its own antibody discovery capabilities. The license enables Talem to develop and partner human antibodies across the platform.
Talem plans to leverage multiple tracks for antibody discovery within ImmunoPrecise’s technology portfolio, including the DeepDisplay custom immune phage libraries.
“ImmunoPrecise has years of experience successfully employing OmniAb animals in antibody discovery,” said Jennifer Bath, CEO of ImmunoPrecise in a statement.
“Combining ImmunoPrecise's end-to-end antibody discovery technologies with Ligand's leading OmniAb platform is a natural progression, supporting both companies' overall mission of getting the best therapeutic antibodies to the clinic faster, in this case, all under one roof.”
With the agreement in place, Talem hopes to streamline the path to the clinic by de-risking lead candidates for potential partners worldwide.
"Enabling Talem's internal discovery for the development of therapeutic antibodies in OmniAb animals provides Talem, and its future partners, a distinctively streamlined path to the clinic,” Bath told investors.
ImmunoPrecise also said that it had parted ways with Jason Orloske, its vice president of operations. The firm wished him well in his future endeavours.
Shares of ImmunoPrecise closed at C$0.60 in Toronto and at US$0.46 on OTC markets on Tuesday.
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas